A multicenter Phase III trial found that intravenous tirofiban did not outperform standard oral antiplatelet therapy for 90-day functional outcomes in acute branch atheromatous disease-related stroke. The result suggests no added benefit for the IV glycoprotein IIb/IIIa approach compared with current oral standard options in this specific clinical context. The study also underscores the importance of patient and biomarker stratification in stroke intervention trials, where outcomes can vary sharply by stroke subtype. For treatment protocols, the trial narrows potential escalation pathways and strengthens reliance on established oral antiplatelet strategies for this patient group.